Brief: Invivyd Announces Initiation Of DECLARATION Clinical Trial, A Phase 3 Placebo-Controlled Pivotal Study Of VYD2311, A Vaccine-Alternative Antibody To Prevent Covid
23/12/2025 12:05
Dec 23 (Reuters) - Invivyd Inc IVVD.O: INVIVYD ANNOUNCES INITIATION OF DECLARATION CLINICAL TRIAL, A PHASE 3 PLACEBO-CONTROLLED PIVOTAL STUDY OF VYD2311, A VACCINE-ALTERNATIVE ANTIBODY TO PREVENT COVID INVIVYD INC - TOP-LINE DATA EXPECTED MID-2026 INVIVYD INC - TRIAL TO ENROLL 1770 PARTICIPANTS FOR COVID INCIDENCE REDUCTION Source text: ID:nGNX8DZLKd Further company coverage: IVVD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invivyd
See all newsBrief: Invivyd Announces Positive Topline Results From Liberty Phase 3 Study Demonstrating Vyd2311 Safety And Tolerability Superior To Mrna-Based Covid-19 Vaccine Announces Regulatory Submission Plans For Vyd2311
Invivyd, Inc. reports results for the quarter ended June 30 - Earnings Summary
Invivyd Q2 loss per share comes wider than expected on higher costs
Brief: Invivyd Q2 EPS USD -0.14
Invivyd, Inc. expected to post a loss of 11 cents a share - Earnings Preview